An interventional study of IPL+LLLT in Dry Eye and Dry Eye After LASIK-Laser in Situ Keratomileusis, sponsored by University Hospital, Brest. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.
Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2023, is one of 28 with no phase, and was the 32nd registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:
TRB Chemedica International SA · Sites in France, Belgium
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
TRB Chemedica International SA · Sites in France, Austria
Ages 18+
AbbVie · Sites in France, United States, Netherlands
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 81 across the 40 interventional studies, 45 across the 7 observational. Of the 29 that completed or were terminated, 12 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 47 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
University Hospital, Brest has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies in Dry Eye Syndromes with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03358979Fondation Ophtalmologique Adolphe de RothschildThree-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) | 2026-12 |
| NCT05865379TRB Chemedica International SAEfficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT05865457TRB Chemedica International SAEfficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 47 studies in Dry Eye Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Laser corneal refractive surgery is a widely adopted approach for correcting refractive errors, but postoperative dry eye remains a common side effect. Intense Pulsed Light (IPL) and Low-Level Light Therapy (LLLT) are two emerging treatments that have shown potential in managing dry eye disease. However, their role as a prophylactic treatment in patients without pre-existing symptomatic dry eye undergoing refractive surgery has not been explored.
monocentric, randomized, simple bling, controlled study
Patients eligible for laser corneal refractive surgery (FS-LASIK, SMILE®, or PRK) who meet the inclusion criteria will be enrolled.
Exclusion criteria include age \< 18 and to IPL or LLLT (e.g., pregnancy, lactation, migraine, epilepsy, palpebral or periocular lesion, photosensitive drugs, cardiac pacing system or implantable cardiovertor defibrillator, Fitzpatrick phototypes V and VI).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group
Device: IPL+LLLT
non preventive treatment by IPL+LLLT with EYE-LIGHT, Espansione group = standard care
preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
French version of Ocular Surface Disease Index (OSDI) score
The OSDI questionnaire measures frequency of symptoms, environmental triggers and vision related quality of life. OSDI values range from 0 to 100. A score between 13 and 22 excluded indicates a medium intensity eye dryness. A score between 22 and 33 indicated a moderate intensity eye dryness. A score above 33 indicates a severe eye dryness.
Time frame: 1 month post-operative
Evolution of Fluorescein Break-up Time (FBUT) over the 6 first months post-operative
Sodium fluorescein eye drops is instilled in the eye to enhance visibility of the tear film measure tear film breakup time is. Selected cut-off value is 10 seconds. A score below 10 seconds favors dry eye.
Time frame: 6 months post-operative
Evolution of Schirmer I test over the 6 first months post-operative
The Schirmer I test, used without anesthesia, provides an estimation of stimulated reflex. Cut-off value used is \<= 10 mm / 5 minutes.
Time frame: 6 months post-operative
Evolution of Meibomian Gland Dropout over the 6 first months post-operative
Meibomian Gland Dropout: Evaluated via infrared images using LipiView™ II (Quantel Medical) and graded using the Gestalt Grading Scale (GGS), which scores meibomian gland loss on a scale from 1 (no loss) to 4 (\>75% loss).
Time frame: 6 months post-operative
Evolution of the Oxford score over the 6 first months post-operative
The Oxford score is composed of 0 to V grades, dependent on intensity of punctate staining displayed. pictorially across a combination of the cornea and conjunctiva.
Time frame: 6 months post-operative
Evolution of visual acuity over the 6 first months post-operative
Visual acuity measured preoperatively (corrected) and postoperatively (uncorrected) using the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale at 4 meters. Visual acuity is scored by adding 30 to the total number of letters read correctly at 4 meters
Time frame: 6 months post-operative
Evolution of the French version of Ocular Surface Disease Index (OSDI) score over the 6 first months post-operative
The OSDI questionnaire measures frequency of symptoms, environmental triggers and vision related quality of life. OSDI values range from 0 to 100. A score between 13 and 22 excluded indicates a medium intensity eye dryness. A score between 22 and 33 indicated a moderate intensity eye dryness. A score above 33 indicates a severe eye dryness.
Time frame: 6 months post-operative
Plan to share: Yes — De-identified (coded/pseudonymised) individual participant data from the TEBeLiD randomized trial that underlie the primary and secondary publications/final study report. Dataset includes baseline demographics/clinical characteristics, randomization group, procedural variables, follow-up outcomes (e.g., F-OSDI/OSDI, tear film break-up time, corneal staining/Oxford score, Schirmer test, meibomian gland assessment/meibography), adverse events, and protocol deviations. A data dictionary and variable coding will be provided.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available beginning five years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest University Hospital (CHU de Brest). Requests must include a research proposal and analysis plan (and ethics approval/exemption if applicable). Approved requestors will be required to sign and comply with a data access/data use agreement (no re-identification; secure storage; no onward sharing; acknowledgement/citation of TEBeLiD investigators). Data will be provided via secure transfer or controlled-access environment.
Ran from Jun 2023 to primary completion in Nov 2024, 17 months.
Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 17 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.